Qutenza box

Request a representative and order your QUTENZA Office Kit today!

*Required

Ordering
Phone Icon

For more information about QUTENZA, please call 1-877-900-6479
(Option 3 for Reimbursement Support and Option 4 for Ordering).

Phone Icon

NEED HELP? Visit the FAQs section for more information about ordering.

Indication:

QUTENZA® (capsaicin) 8% Patch is indicated for the management of neuropathic pain associated with postherpetic neuralgia.

IMPORTANT SAFETY INFORMATION:

Only physicians or healthcare professionals under the close supervision of a physician are to administer QUTENZA.

Contraindications:

None

Warnings and Precautions:

  • Do not apply QUTENZA to the face or scalp to avoid risk of exposure to the eyes or mucous membranes.
  • Aerosolization of capsaicin can occur and inhalation may result in coughing or sneezing.
  • If skin not intended to be treated comes into contact with QUTENZA, clean area using Cleansing Gel.
  • Patients may experience substantial procedural pain. Prepare to treat pain with local cooling (such as a cold pack) and/or appropriate analgesic medication.
  • Transient increases in blood pressure may occur during and shortly after the QUTENZA treatment. Blood pressure changes were associated with treatment-related increases in pain. Monitor blood pressure and provide adequate support for treatment-related pain. Patients with unstable or poorly controlled hypertension or a recent history of cardiovascular or cerebrovascular events may be at an increased risk of adverse cardiovascular effects. Consider these factors prior to initiating QUTENZA treatment.
  • If opioids are used to treat pain associated with the application procedure, please note that opioid treatment may affect the patient's ability to perform potentially hazardous activities such as driving or operating heavy machinery.

Adverse Reactions:

In clinical trials, serious adverse reactions included application associated pain and increase in blood pressure. The most common adverse reactions (≥ 5% and greater than control) were application-site erythema, application-site pain, application-site pruritus, or application-site papules, and nausea.

To report an adverse event, you can visit www.fda.gov/medwatch or call at 1-800-FDA-1088; or you can call Averitas Pharma, Inc. at 1-877-900-6479.

Please see full Prescribing Information.

Carton with one patch + cleansing gel: NDC #72512-928-01
Carton with two patches + cleansing gel: NDC #72512-929-01

Indication:

QUTENZA® (capsaicin) 8% Patch is indicated for the management of neuropathic pain associated with postherpetic neuralgia.

IMPORTANT SAFETY INFORMATION:

Only physicians or healthcare professionals under the close supervision of a physician are to administer QUTENZA.

Contraindications:

None

Warnings and Precautions:

  • Do not apply QUTENZA to the face or scalp to avoid risk of exposure to the eyes or mucous membranes.
  • Aerosolization of capsaicin can occur and inhalation may result in coughing or sneezing.
  • If skin not intended to be treated comes into contact with QUTENZA, clean area using Cleansing Gel.
  • Patients may experience substantial procedural pain. Prepare to treat pain with local cooling (such as a cold pack) and/or appropriate analgesic medication.
  • Transient increases in blood pressure may occur during and shortly after the QUTENZA treatment. Blood pressure changes were associated with treatment-related increases in pain. Monitor blood pressure and provide adequate support for treatment-related pain. Patients with unstable or poorly controlled hypertension or a recent history of cardiovascular or cerebrovascular events may be at an increased risk of adverse cardiovascular effects. Consider these factors prior to initiating QUTENZA treatment.
  • If opioids are used to treat pain associated with the application procedure, please note that opioid treatment may affect the patient's ability to perform potentially hazardous activities such as driving or operating heavy machinery.

Adverse Reactions:

In clinical trials, serious adverse reactions included application associated pain and increase in blood pressure. The most common adverse reactions (≥ 5% and greater than control) were application-site erythema, application-site pain, application-site pruritus, or application-site papules, and nausea.

To report an adverse event, you can visit www.fda.gov/medwatch or call at 1-800-FDA-1088; or you can call Averitas Pharma, Inc. at 1-877-900-6479.

Please see full Prescribing Information.

Carton with one patch + cleansing gel: NDC #72512-928-01
Carton with two patches + cleansing gel: NDC #72512-929-01

Reference: 1. QUTENZA® [prescribing information]. Morristown, NJ: Averitas Pharma, Inc.